MA29935B1 - Inhibiteurs de l'activite de akt - Google Patents

Inhibiteurs de l'activite de akt

Info

Publication number
MA29935B1
MA29935B1 MA30904A MA30904A MA29935B1 MA 29935 B1 MA29935 B1 MA 29935B1 MA 30904 A MA30904 A MA 30904A MA 30904 A MA30904 A MA 30904A MA 29935 B1 MA29935 B1 MA 29935B1
Authority
MA
Morocco
Prior art keywords
inhibitors
akt activity
activity
compounds
imidazo
Prior art date
Application number
MA30904A
Other languages
English (en)
Inventor
Dirk A Heerding
Tammy J Clark
Jack Dale Leber
Igor Safonov
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of MA29935B1 publication Critical patent/MA29935B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'INVENTION CONCERNE DE NOUVEAUX COMPOSÉS 1 H-IMIDAZO[4,5-C];PYRIDIN-2-YL, L'UTILISATION DE CES COMPOSÉS EN TANT QU'INHIBITEURS DE L'ACTIVITÉ DE LA PROTÉINE KINASE B, ET POUR LE TRAITEMENT DU CANCER ET DE L'ARTHRITE.
MA30904A 2005-11-10 2008-05-05 Inhibiteurs de l'activite de akt MA29935B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US73595505P 2005-11-10 2005-11-10
US77228906P 2006-02-10 2006-02-10
US82692806P 2006-09-26 2006-09-26

Publications (1)

Publication Number Publication Date
MA29935B1 true MA29935B1 (fr) 2008-11-03

Family

ID=38049129

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30904A MA29935B1 (fr) 2005-11-10 2008-05-05 Inhibiteurs de l'activite de akt

Country Status (16)

Country Link
US (1) US20100056523A1 (fr)
EP (1) EP1948188A4 (fr)
JP (1) JP2009516653A (fr)
KR (1) KR20080067646A (fr)
AP (1) AP2008004442A0 (fr)
AR (1) AR056786A1 (fr)
AU (1) AU2006315805A1 (fr)
BR (1) BRPI0618309A2 (fr)
CA (1) CA2629429A1 (fr)
EA (1) EA200801301A1 (fr)
EC (1) ECSP088425A (fr)
IL (1) IL190968A0 (fr)
MA (1) MA29935B1 (fr)
NO (1) NO20082414L (fr)
TW (1) TW200736260A (fr)
WO (1) WO2007058850A2 (fr)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1948185A4 (fr) * 2005-11-10 2010-04-21 Glaxosmithkline Llc Inhibiteurs de l'activite de l'akt
KR20180090396A (ko) 2008-01-18 2018-08-10 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 체액 내에서 질병 또는 병태의 시그너쳐의 검출 방법
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
JP2011521214A (ja) * 2008-05-16 2011-07-21 セルゾーム アーゲー Ｐａｒｐ相互作用分子の同定およびｐａｒｐタンパク質の精製のための方法
JP2011525915A (ja) * 2008-06-26 2011-09-29 アムジエン・インコーポレーテツド キナーゼ阻害薬としてのアルキニルアルコール類
MX2011004953A (es) 2008-11-10 2011-12-14 Vertex Pharma Compuestos utiles como inhibidores de cinasa atr.
ES2921576T3 (es) 2008-12-19 2022-08-29 Vertex Pharma Compuestos útiles como inhibidores de la quinasa ATR
EP2569313A1 (fr) 2010-05-12 2013-03-20 Vertex Pharmaceuticals Incorporated Composés utiles comme inhibiteurs de la kinase atr
US9334244B2 (en) 2010-05-12 2016-05-10 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
WO2011143419A1 (fr) 2010-05-12 2011-11-17 Vertex Pharmaceuticals Incorporated Pyrazines utiles en tant qu'inhibiteurs de la kinase atr
US8969356B2 (en) 2010-05-12 2015-03-03 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
EP2569286B1 (fr) 2010-05-12 2014-08-20 Vertex Pharmaceuticals Inc. Composés utilisables en tant qu'inhibiteurs de la kinase atr
NZ603478A (en) 2010-05-12 2014-09-26 Vertex Pharma 2 -aminopyridine derivatives useful as inhibitors of atr kinase
EP2585468A1 (fr) 2010-06-23 2013-05-01 Vertex Pharmaceuticals Incorporated Dérivés de pyrrolo-pyrazine utiles en tant qu'inhibiteurs de l'atr kinase
AU2011280944A1 (en) * 2010-07-23 2013-02-28 President And Fellows Of Harvard College Methods of detecting diseases or conditions using phagocytic cells
AU2011280997A1 (en) 2010-07-23 2013-02-28 President And Fellows Of Harvard College Methods of detecting autoimmune or immune-related diseases or conditions
AU2011280936A1 (en) 2010-07-23 2013-02-28 President And Fellows Of Harvard College Methods of detecting prenatal or pregnancy-related diseases or conditions
US8901313B2 (en) 2011-03-16 2014-12-02 Genentech, Inc. 6,5-heterocyclic propargylic alcohol compounds and uses therefor
AU2012240030A1 (en) 2011-04-05 2013-10-24 Vertex Pharmaceuticals Incorporated Aminopyrazine compounds useful as inhibitors of TRA kinase
WO2012178123A1 (fr) 2011-06-22 2012-12-27 Vertex Pharmaceuticals Incorporated Composés utiles comme inhibiteurs de la kinase atr
US9309250B2 (en) 2011-06-22 2016-04-12 Vertex Pharmaceuticals Incorporated Substituted pyrrolo[2,3-b]pyrazines as ATR kinase inhibitors
EP2723747A1 (fr) 2011-06-22 2014-04-30 Vertex Pharmaceuticals Inc. Composés utiles comme inhibiteurs de la kinase atr
US8765751B2 (en) 2011-09-30 2014-07-01 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
WO2013049720A1 (fr) 2011-09-30 2013-04-04 Vertex Pharmaceuticals Incorporated Composés utiles en tant qu'inhibiteurs de kinase atr
RU2018108589A (ru) 2011-09-30 2019-02-25 Вертекс Фармасьютикалз Инкорпорейтед Лечение рака поджелудочной железы и немелкоклеточного рака легкого ингибиторами atr
EP3878851A1 (fr) 2011-09-30 2021-09-15 Vertex Pharmaceuticals Incorporated Procédé de préparation de composés utiles en tant qu'inhibiteurs de kinase d'atr
CA2850564A1 (fr) 2011-09-30 2013-04-04 Vertex Pharmaceuticals Incorporated Composes utiles comme inhibiteurs de kinase atr
EP2776420A1 (fr) 2011-11-09 2014-09-17 Vertex Pharmaceuticals Incorporated Composés de pyrazine utiles comme inhibiteurs de kinase atr
JP2015502925A (ja) 2011-11-09 2015-01-29 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Ａｔｒキナーゼの阻害剤として有用なピラジン化合物
WO2013071090A1 (fr) 2011-11-09 2013-05-16 Vertex Pharmaceuticals Incorporated Composés utiles en tant qu'inhibiteurs de la kinase atr
US8846917B2 (en) 2011-11-09 2014-09-30 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
EP2776429A1 (fr) 2011-11-09 2014-09-17 Vertex Pharmaceuticals Incorporated Composés utiles comme inhibiteurs de kinase atr
PT2833973T (pt) 2012-04-05 2017-12-21 Vertex Pharma Compostos úteis como inibidores da cinase atr e terapias de combinação dos mesmos
WO2014055756A1 (fr) 2012-10-04 2014-04-10 Vertex Pharmaceuticals Incorporated Procédé pour la mesure d'augmentations de lésions d'adn à médiation par l'inhibition d'atr
EP2909202A1 (fr) 2012-10-16 2015-08-26 Vertex Pharmaceuticals Incorporated Composés utiles en tant qu'inhibiteurs de la kinase atr
WO2014089379A1 (fr) 2012-12-07 2014-06-12 Vertex Pharmaceuticals Incorporated Composés utiles en tant qu'inhibiteurs d'atr kinase
NZ771629A (en) 2013-03-09 2022-12-23 Harry Stylli Methods of detecting cancer
US9663519B2 (en) 2013-03-15 2017-05-30 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
TWI663166B (zh) 2013-04-24 2019-06-21 健生藥品公司 新化合物
EP3013818B1 (fr) * 2013-06-26 2021-12-29 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) (s)-énantiomère de mepazine en tant qu'inhibiteur de paracaspase (malt1) pour le traitement du cancer
CA2938626A1 (fr) 2013-07-26 2015-01-29 John Rothman Compositions permettant d'ameliorer l'avantage therapeutique du bisantrene
TWI627173B (zh) * 2013-09-26 2018-06-21 比利時商健生藥品公司 作為ＮＩＫ抑制劑的新穎３－（１Ｈ－吡唑－４－基）－１Ｈ－吡咯并［２，３－ｃ］吡啶衍生物
TWI704146B (zh) * 2013-09-26 2020-09-11 比利時商健生藥品公司 用作ＮＩＫ抑制劑之新的1-(４-嘧啶基)-１Ｈ-吡唑並[３,２-ｃ]吡啶衍生物
WO2015085132A1 (fr) 2013-12-06 2015-06-11 Vertex Pharmaceuticals Incorporated Compose 2-amino -6-fluoro-n- [5-fluoro-pyridin -3-yl] pyrazolo [1,5-a] pyrimidine-3-carboxamide utile comme inhibiteur de la kinase atr, sa préparation, différentes formes solides et dérivés radiomarqués de celui-ci
HRP20200186T1 (hr) 2014-06-05 2020-05-29 Vertex Pharmaceuticals Inc. Radioaktivno obilježeni derivati 2-amino-6-fluoro-n-[5-fluoro-piridin-3-il]-pirazolo[1,5-a]pirimidin-3-karboksamid spojeva koji se koriste kao inhibitori atr kinaze, priprava navedenih spojeva i njihovi različiti čvrsti oblici
JP6936007B2 (ja) 2014-06-17 2021-09-15 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Ｃｈｋ１阻害剤とａｔｒ阻害剤との組み合わせを使用してがんを処置する方法
CA2960574C (fr) 2014-10-23 2023-03-07 Janssen Pharmaceutica Nv Derives de pyrazolopyrimidine comme inhibiteurs de nik
CN107074818B (zh) 2014-10-23 2020-04-17 詹森药业有限公司 作为nik抑制剂的吡唑衍生物
AU2015334917B2 (en) 2014-10-23 2019-08-29 Janssen Pharmaceutica Nv New compounds as NIK inhibitors
JP6603713B2 (ja) 2014-10-23 2019-11-06 ヤンセン ファーマシューティカ エヌ．ベー． Ｎｉｋ阻害剤としての新規のチエノピリミジン誘導体
EP3355926B1 (fr) 2015-09-30 2025-12-24 Vertex Pharmaceuticals Inc. Association d'agents endommageant l'adn et d'inhibiteurs de l'atr pour son utilisation dans une méthode de traitement du cancer
CN112888440A (zh) 2018-10-16 2021-06-01 豪夫迈·罗氏有限公司 Akt抑制剂在眼科中的用途
FI3873903T3 (fi) 2018-10-31 2024-03-26 Gilead Sciences Inc Substituoituja 6-azabentsiimidatsoliyhdisteitä HPK1-inhibiittoreina
KR102658602B1 (ko) 2018-10-31 2024-04-19 길리애드 사이언시즈, 인코포레이티드 Hpk1 억제 활성을 갖는 치환된 6-아자벤즈이미다졸 화합물
TWI826690B (zh) 2019-05-23 2023-12-21 美商基利科學股份有限公司 經取代之烯吲哚酮化物及其用途
CN119278041A (zh) 2022-03-31 2025-01-07 阿斯利康(瑞典)有限公司 用于治疗癌症的与akt抑制剂组合的表皮生长因子受体（egfr）酪氨酸激酶抑制剂
IL320302A (en) 2022-10-17 2025-06-01 Astrazeneca Ab SERD combinations for cancer treatment
CN120187416A (zh) 2022-11-11 2025-06-20 阿斯利康(瑞典)有限公司 用于治疗癌症的组合疗法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200523262A (en) * 2003-07-29 2005-07-16 Smithkline Beecham Corp Inhibitors of AKT activity

Also Published As

Publication number Publication date
TW200736260A (en) 2007-10-01
WO2007058850A2 (fr) 2007-05-24
US20100056523A1 (en) 2010-03-04
JP2009516653A (ja) 2009-04-23
WO2007058850A3 (fr) 2009-04-30
AU2006315805A1 (en) 2007-05-24
EP1948188A2 (fr) 2008-07-30
EA200801301A1 (ru) 2009-02-27
AP2008004442A0 (en) 2008-04-30
ECSP088425A (es) 2008-06-30
IL190968A0 (en) 2009-02-11
AR056786A1 (es) 2007-10-24
EP1948188A4 (fr) 2011-02-16
NO20082414L (no) 2008-08-05
CA2629429A1 (fr) 2007-05-24
BRPI0618309A2 (pt) 2011-08-23
KR20080067646A (ko) 2008-07-21

Similar Documents

Publication Publication Date Title
MA29935B1 (fr) Inhibiteurs de l'activite de akt
MA27933A1 (fr) Inhibiteurs de l'activite de akt
MA31167B1 (fr) Inhibiteurs de l'activite de akt
NO20082476L (no) Bicykliske forbindelser med kinaseinhiberende aktivitet
NO20076651L (no) Fremgangsmate for fremstilling av 2-metyl-l-(2-metylpropyl)-1H-imidazo[4,5-c] [1,5]naftyridin-4-amin
NO20091618L (no) Bicykliske triazoler som proteinkinasemodulatorer
ATE301653T1 (de) Pyrazolopyridine
EP1638950A4 (fr) Derives de cyclohexylglycine servant d'inhibiteurs de la dipeptidyl peptidase pour le traitement ou la prevention du diabete
DE60214703D1 (de) Thiazolverbindungen, die sich als inhibitoren von proteinkinasen eignen
ATE551340T1 (de) Azabicyclisch- substituierte annelierte heteroaryl-verbinungen für die behandlung von krankheiten
DE60108754D1 (de) Substituierte bizyklische derivate für die behandlung von unnormalem zellwachstum
ATE430747T1 (de) 2-pyrimidinyl-pyrazolopyridin-erbb- kinaseinhibitoren
ATE384061T1 (de) Imidazo- und thiazolopyridine als jak3-kinase- inhibitoren
BR112013008140A2 (pt) "compostos imidazotriazinona".
ATE493418T1 (de) Dihydrofuropyrimidine als akt- proteinkinaseinhibitoren
ATE532789T1 (de) Dihydrothienopyrimidine als akt-proteinkinase- inhibitoren
TW200635591A (en) 1-(2-methylpropyl)-1H-imidazo[4,5-c][1,5]naphthyridin-4-amine ethanesulfonate and 1-(2-methylpropyl)-1H-imidazo[4,5-c][1,5]naphthyridin-4-amine methanesulfonate
MA28567B1 (fr) Utilisation de beta-carbolines pour le traitement de maladies inflammatoires
TW200716110A (en) Inhibitors of AKT activity
MX2008011576A (es) Compuestos de imidazo[2,1-b]tiazol sustituidos y su uso para la produccion de farmacos.
ATE373000T1 (de) Pyrazolopyridin-derivate als antiherpesmittel
ATE433450T1 (de) Substituierte 1,4,8-triazaspiro 4.5 decan-2-on- verbindungen
WO2007058852A3 (fr) Inhibiteurs de l’activite de l’akt
WO2007058879A3 (fr) Inhibiteurs de l'activité de akt
SE0100295D0 (sv) New compounds